MASI

Masimo Corporation (MASI) | Rumor.io

Masimo

MASI

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio44.4

Market capitalization160.8B

Earnings per share4.05

Dividend yield (TTM)—

Revenue (annual)1.5B

Net income (annual)-151.5M

Social

What share of all stock conversation is about MASI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

May 23

MASI's Fear & Greed Index is at 31, indicating a fear zone.
This may be a good time to accumulate shares of Masimo Corporation.
MASI is a stock to consider investing in this week.

Generated by AI

Sentiment

Of the messages about MASI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% 0	89.68% +32.91
Bearish	0%	0%	0% 0	10.32% -32.91

Bullish· Feb 18

Masimo Corporation ($MASI) has seen a massive surge of 34% to $174.69, with 14.82M shares traded, confirming institutional conviction and a breakout above the $147.16 resistance level.
The acquisition of Masimo by Danaher for $180 per share, a 40% premium, has been a major catalyst for the stock's move, with the deal's announcement likely to have cleared regulatory overhang and paved the way for continued momentum.
The stock's impressive cash flow generation and relative strength in a lower market open highlight its high-risk, high-reward opportunity, with a measured move target projecting to $246.76.

Bearish· Jul 18

$MASI's preliminary Q2 revenue fell short of consensus, with a projected range of $453M-$457M compared to a consensus estimate of $553.23M.
The company's guidance was cut by almost 50%, with projected Q2 revenue declining 20% from the previous quarter and FY23 sales in its healthcare business slipping 10% below prior predictions.
Analysts have downgraded the stock significantly, with one analyst nearly halving their price target, and the risk/reward favoring a short position in the near term.

Generated by AI

Topics

Of the messages about MASI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	15.53%
Announcements	100%	100%	97.06%	51.63%
Controversies	0%	0%	0%	5.21%
Earnings	0%	0%	2.94%	11.35%
Macro	0%	0%	0%	12.37%
Technical Analysis	0%	0%	0%	3.91%

Earnings· May 2

Masimo Corporation ($MASI) reported Q1 2018 earnings of 75c EPS and $212.95M revenue, beating estimates.
$MASI beats Estimize EPS Consensus by 1c and Revenue Consensus by $0.55M.
Masimo updates FY18 guidance to $2.88 EPS.

Announcements· Feb 17

Danaher is set to acquire Masimo in a $9.9 billion all-cash deal, valuing the company at $180 per share.
The acquisition represents a significant premium to Masimo's prior market value, with the company's shares surging 34% on the news.
The deal is expected to be immediately accretive to Danaher's adjusted earnings per share, with the company forecasting 15-20 cents of additional earnings in the first full year and 70 cents by year five.

Controversies· Jan 17

An appeals court has reinstated a ban on Apple's Apple Watch Series 9 and Ultra 2 models with a blood oxygen feature in the US, citing patent infringement by Masimo Corporation.
The ban, which was initially paused, will be effective as of January 18, 2024, and requires Apple to stop selling the affected watches in the US.
Masimo's stock has increased by 1.3% following the court's decision, as the company's patents on blood-oxygen level sensor technology are found to be infringed upon by Apple's watches.

Technical Analysis· Feb 16

$MASI is expected to recover to $180 based on charts, with a potential steady climb for the remainder of the day.
The stock has formed a bull flag, indicating a strong buying opportunity with a risk-reward ratio favoring the bulls.
$MASI has broken out of the oversold zone on the RSI indicator and is in an uptrend, with a potential retest of the 135 support level.

Generated by AI

Community

Of the messages about MASI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	13.33%	21.11%	24.72%
Newcomers	0%	86.67%	78.89%	75.28%

Regulars· Feb 17

Masimo Corporation (MASI) has agreed to be acquired by Danaher for $180 per share in cash, valuing the deal at approximately $9.9 billion, with the transaction expected to close in the second half of 2026.
The acquisition is expected to strengthen Danaher's diagnostics segment and add 15-20 cents to adjusted earnings per share in the first full year, rising to 70 cents by year five, with Masimo operating as a standalone unit within the division.
Danaher expects to generate over $125 million in annual cost savings by the fifth year after closing, with Masimo reporting preliminary 2025 revenue of $1.52 billion, up 9%, and projected to generate more than $530 million in EBITDA by 2027.

Newcomers· Feb 18

The acquisition of Masimo Corporation by Danaher has led to a significant surge in the stock price, with a 34.22% increase to $174.69.
Newcomers are focused on the potential benefits of the acquisition, with some noting that Danaher is buying Masimo at a low point, which could be a good opportunity for the company.
The acquisition has also sparked discussion about the company's future prospects, with some highlighting its leading position in the global pulse oximetry and advanced non-invasive patient monitoring market.

Generated by AI

Earlier in 2026, Masimo voluntarily initiated global Class II recalls of certain Radius VSM ECG assemblies and blood pressure cuffs after identifying risks of false heart-rate alarms and potential skin irritation from rough cuff edges, affecting more than 1,800 devices distributed across the US and multiple international markets. Because these issues touch core patient-monitoring functions that clinicians rely on, the recalls raise meaningful questions about product reliability, regulatory...

2mo agoYahoo Finance

Masimo (MASI) Following Recall News Why The Stock Still Looks Fairly Valued

Masimo (MASI) has drawn fresh investor attention after voluntarily recalling specific Radius VSM disposable blood pressure cuffs and ECG pre connected sets, citing possible ECG alarm inaccuracies and skin irritation risks across a globally distributed inventory. See our latest analysis for Masimo. Set against the recent recall headlines, Masimo’s share price return of 41.25% year to date and 2.55% over 90 days suggests investors are still pricing in improving sentiment, even though the 5 year...

2mo agoYahoo Finance

Can Masimo’s Integration and Bioprocessing Strength Reshape Danaher’s Long-Term Story (DHR)?

Danaher, which released its Q2 2026 results on 21 July, saw expectations firm up ahead of the report as analysts projected modest year-on-year growth in revenue and earnings, helped by solid bioprocessing demand, improved filtration activity, and contributions from the Masimo acquisition despite cost pressures and higher debt. Investors are focusing on how Masimo’s integration and continued strength in bioprocessing and diagnostics could offset weaker areas like Diagnostics and rising input,...

2mo agoYahoo Finance

Oh dear, did someone steal something from Apple?

Apple says OpenAI stole its trade secrets. Here's how Apple has faced similar accusations from rivals in the past.

2mo agoBusiness Insider

Also Discussed

Investors talking about MASI also mention

#	Name	Attention
1	Teleflex IncorporatedTFX	0%+0
2	Intuitive Surgical Inc.ISRG	0%0
3	Stryker CorporationSYK	0.01%+0.01
4	111, Inc. ADRYI	0%0
5	DexCom Inc.DXCM	0%0
6	ABMD - Abiomed, Inc.	——
7	Falcon's Beyond Global, Inc. Class A Common StockFBYD	0%new
8	HealthEquity, Inc.HQY	0%new
9	Ensign Group Inc-TheENSG	0%new
10	MKDWELL Tech Inc.MKDW	0%+0

Masimo Corporation

Healthcare
Medical Devices

Masimo Corporation is a global medical technology company that develops, manufactures, and markets innovative noninvasive patient monitoring technologies, sensors, patient monitors, and automation and connectivity solutions. Its healthcare segment, the primary revenue driver, focuses on hospital automation platforms like Masimo Hospital Automation™ and Masimo SafetyNet®, alongside remote patient monitoring, telehealth, and telemonitoring devices to enhance care delivery in hospitals and beyond. Notable technologies include Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which excels in challenging conditions and is widely used in top hospitals. The company also offers consumer health products. Previously encompassing a non-healthcare segment for premium audio products, Masimo Corporation has divested that business to concentrate on medical innovations. Founded in 1987 and headquartered in Irvine, California, it plays a vital role in advancing patient safety and clinical efficiency across healthcare settings worldwide.

Website

Location

52 Discovery

Irvine, CA, 92618

United States

Social

What share of all stock conversation is about MASI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

May 23

MASI's Fear & Greed Index is at 31, indicating a fear zone.
This may be a good time to accumulate shares of Masimo Corporation.
MASI is a stock to consider investing in this week.

Generated by AI

Sentiment

Of the messages about MASI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% 0	89.68% +32.91
Bearish	0%	0%	0% 0	10.32% -32.91

Bullish· Feb 18

Masimo Corporation ($MASI) has seen a massive surge of 34% to $174.69, with 14.82M shares traded, confirming institutional conviction and a breakout above the $147.16 resistance level.
The acquisition of Masimo by Danaher for $180 per share, a 40% premium, has been a major catalyst for the stock's move, with the deal's announcement likely to have cleared regulatory overhang and paved the way for continued momentum.
The stock's impressive cash flow generation and relative strength in a lower market open highlight its high-risk, high-reward opportunity, with a measured move target projecting to $246.76.

Bearish· Jul 18

$MASI's preliminary Q2 revenue fell short of consensus, with a projected range of $453M-$457M compared to a consensus estimate of $553.23M.
The company's guidance was cut by almost 50%, with projected Q2 revenue declining 20% from the previous quarter and FY23 sales in its healthcare business slipping 10% below prior predictions.
Analysts have downgraded the stock significantly, with one analyst nearly halving their price target, and the risk/reward favoring a short position in the near term.

Generated by AI

Topics

Of the messages about MASI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	15.53%
Announcements	100%	100%	97.06%	51.63%
Controversies	0%	0%	0%	5.21%
Earnings	0%	0%	2.94%	11.35%
Macro	0%	0%	0%	12.37%
Technical Analysis	0%	0%	0%	3.91%

Earnings· May 2

Masimo Corporation ($MASI) reported Q1 2018 earnings of 75c EPS and $212.95M revenue, beating estimates.
$MASI beats Estimize EPS Consensus by 1c and Revenue Consensus by $0.55M.
Masimo updates FY18 guidance to $2.88 EPS.

Announcements· Feb 17

Danaher is set to acquire Masimo in a $9.9 billion all-cash deal, valuing the company at $180 per share.
The acquisition represents a significant premium to Masimo's prior market value, with the company's shares surging 34% on the news.
The deal is expected to be immediately accretive to Danaher's adjusted earnings per share, with the company forecasting 15-20 cents of additional earnings in the first full year and 70 cents by year five.

Controversies· Jan 17

An appeals court has reinstated a ban on Apple's Apple Watch Series 9 and Ultra 2 models with a blood oxygen feature in the US, citing patent infringement by Masimo Corporation.
The ban, which was initially paused, will be effective as of January 18, 2024, and requires Apple to stop selling the affected watches in the US.
Masimo's stock has increased by 1.3% following the court's decision, as the company's patents on blood-oxygen level sensor technology are found to be infringed upon by Apple's watches.

Technical Analysis· Feb 16

$MASI is expected to recover to $180 based on charts, with a potential steady climb for the remainder of the day.
The stock has formed a bull flag, indicating a strong buying opportunity with a risk-reward ratio favoring the bulls.
$MASI has broken out of the oversold zone on the RSI indicator and is in an uptrend, with a potential retest of the 135 support level.

Generated by AI

Community

Of the messages about MASI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	13.33%	21.11%	24.72%
Newcomers	0%	86.67%	78.89%	75.28%

Regulars· Feb 17

Masimo Corporation (MASI) has agreed to be acquired by Danaher for $180 per share in cash, valuing the deal at approximately $9.9 billion, with the transaction expected to close in the second half of 2026.
The acquisition is expected to strengthen Danaher's diagnostics segment and add 15-20 cents to adjusted earnings per share in the first full year, rising to 70 cents by year five, with Masimo operating as a standalone unit within the division.
Danaher expects to generate over $125 million in annual cost savings by the fifth year after closing, with Masimo reporting preliminary 2025 revenue of $1.52 billion, up 9%, and projected to generate more than $530 million in EBITDA by 2027.

Newcomers· Feb 18

The acquisition of Masimo Corporation by Danaher has led to a significant surge in the stock price, with a 34.22% increase to $174.69.
Newcomers are focused on the potential benefits of the acquisition, with some noting that Danaher is buying Masimo at a low point, which could be a good opportunity for the company.
The acquisition has also sparked discussion about the company's future prospects, with some highlighting its leading position in the global pulse oximetry and advanced non-invasive patient monitoring market.

Generated by AI

Masimo

Social

May 23

Bullish· Feb 18

Bearish· Jul 18

Earnings· May 2

Announcements· Feb 17

Controversies· Jan 17

Technical Analysis· Feb 16

Regulars· Feb 17

Newcomers· Feb 18

Should Masimo’s Radius VSM Safety Recalls Prompt a Reassessment From Masimo (MASI) Investors?

Masimo (MASI) Following Recall News Why The Stock Still Looks Fairly Valued

Can Masimo’s Integration and Bioprocessing Strength Reshape Danaher’s Long-Term Story (DHR)?

Oh dear, did someone steal something from Apple?

Also Discussed

Masimo Corporation

Company Information

Location

Should Masimo’s Radius VSM Safety Recalls Prompt a Reassessment From Masimo (MASI) Investors?

Masimo (MASI) Following Recall News Why The Stock Still Looks Fairly Valued

Can Masimo’s Integration and Bioprocessing Strength Reshape Danaher’s Long-Term Story (DHR)?

Oh dear, did someone steal something from Apple?

Also Discussed

Social

May 23

Bullish· Feb 18

Bearish· Jul 18

Earnings· May 2

Announcements· Feb 17

Controversies· Jan 17

Technical Analysis· Feb 16

Regulars· Feb 17

Newcomers· Feb 18